Targets › CFTR
13 programs from 10 companies in 18 trials: 6 Phase 2, 6 Phase 3, 3 Phase 4, 3 Phase 1; Respiratory, Gastroenterology, Other; next expected readout Nov 2026.
Epithelial ion channel that plays an important role in the regulation of epithelial ion and water transport and fluid homeostasis. Mediates the transport of chloride ions across the cell membrane. (UniProt, P13569)
Open in Phaseline: the race on CFTR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Vertex Pharmaceuticals | Ivacaftor Cystic fibrosis transmembrane conductance regulator positive modulator; Cystic fibrosis transmembrane conductance regulator activator | CFTR | Phase 3 | Cystic Fibrosis; Cystic Fibrosis (CF) | Apr 2027 |
| Vertex Pharmaceuticals | Tezacaftor Cystic fibrosis transmembrane conductance regulator positive modulator | CFTR | Phase 3 | Cystic Fibrosis; Cystic Fibrosis (CF) | Apr 2027 |
| Tehran University of Medical Sciences | N-Acetylcysteine Mucolytic agent and antioxidant; breaks disulfide bonds in mucoproteins and provides antio | CFTR | Phase 3 | Oral Mucositis | – |
| Vertex Pharmaceuticals | VX-121/TEZ/D-IVA CFTR modulator combination: VX-121 (CFTR potentiator) + tezacaftor (CFTR corrector) + deut | CFTR | Phase 3 | Cystic Fibrosis | – |
| ReCode Therapeutics | RCT2100 CFTR mRNA therapeutic | CFTR | Phase 2 | Cystic Fibrosis | Nov 2026 |
| Napo Pharmaceuticals | Crofelemer Cystic fibrosis transmembrane conductance regulator inhibitor; Anoctamin-1 blocker | CFTR, ANO1 | Phase 2 | Microvillus Inclusion Disease | Dec 2026 |
| Napo Therapeutics | Crofelemer Cystic fibrosis transmembrane conductance regulator inhibitor; Anoctamin-1 blocker | CFTR, ANO1 | Phase 2 | Short Bowel Syndrome | Mar 2027 |
| Qanatpharma | Lumacaftor Cystic fibrosis transmembrane conductance regulator stabiliser | CFTR | Phase 2 | Heart Failure With Reduced Ejection Fraction | May 2027 |
| 4D Molecular Therapeutics | 4D-710 AAV gene therapy delivering human CFTR with regulatory domain deletion (CFTRΔR) | CFTR | Phase 2 | Cystic Fibrosis Lung | Jun 2027 |
| Arcturus Therapeutics | ARCT-032 CFTR mRNA formulated in lipid nanoparticles | CFTR | Phase 2 | Cystic Fibrosis | Jun 2027 |
| Krystal Biotech | KB407 Replication-defective HSV-1 expressing full-length human CFTR | CFTR | Phase 1 | Cystic Fibrosis | Dec 2026 |
| Boehringer Ingelheim | BI 3720931 (Lenticlair™-ON) Gene therapy for cystic fibrosis | CFTR | Phase 1 | Cystic Fibrosis | Oct 2040 |
| Vertex Pharmaceuticals | VX-522 mRNA therapy encoding CFTR | CFTR | Phase 1 | Cystic Fibrosis | – |
Cystic Fibrosis (11) Cystic Fibrosis (CF) (2) Microvillus Inclusion Disease (1) Cystic Fibrosis Lung (1) Short Bowel Syndrome (1) Heart Failure With Reduced Ejection Fraction (1) Oral Mucositis (1)
small molecule (8), protein or peptide (3), other (1), mixed (1)
Vertex Pharmaceuticals (4) Napo Pharmaceuticals (1) 4D Molecular Therapeutics (1) ReCode Therapeutics (1) Napo Therapeutics (1) Qanatpharma (1) Krystal Biotech (1) Boehringer Ingelheim (1) Arcturus Therapeutics (1) Tehran University of Medical Sciences (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.